{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T20:40:39Z","timestamp":1724359239401},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1053\/j.ajkd.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T03:57:59Z","timestamp":1721361479000},"page":"263-266","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visceral Abdominal Adiposity and Autosomal Dominant Polycystic Kidney Disease Progression: One More Step Toward Identifying Useful Biomarkers and Characterizing the Disease Metabolic Links"],"prefix":"10.1053","volume":"84","author":[{"given":"Elieser Hitoshi","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Fernando","family":"Onuchic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2024.05.005_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.ajkd.2024.02.014","article-title":"Visceral adiposity and progression of ADPKD: a cohort study of patients from the TEMPO 3:4 Trial","volume":"84","author":"Nowak","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.05.005_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc\u00a0Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.05.005_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2024.05.005_bib4","first-page":"1006","article-title":"Type of PKD1\u00a0mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am\u00a0Soc Nephrol"},{"issue":"24","key":"10.1053\/j.ajkd.2024.05.005_bib5","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in\u00a0early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J\u00a0Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.05.005_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2024.05.005_bib7","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J\u00a0Med"},{"issue":"6","key":"10.1053\/j.ajkd.2024.05.005_bib8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.05.005_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2021","journal-title":"iScience"},{"key":"10.1053\/j.ajkd.2024.05.005_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.962933","article-title":"Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease","volume":"9","author":"Iliuta","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1053\/j.ajkd.2024.05.005_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11906-008-0008-z","article-title":"Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk","volume":"10","author":"Calabro","year":"2008","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2024.05.005_bib12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.05.005_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13293-019-0247-5","article-title":"Sex differences in the metabolic effects of the renin-angiotensin system","volume":"10","author":"White","year":"2019","journal-title":"Biol Sex Differ"},{"issue":"11","key":"10.1053\/j.ajkd.2024.05.005_bib14","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.3390\/ijms22116019","article-title":"Gender-dependent phenotype in polycystic kidney disease is determined by differential intracellular Ca2+ signals","volume":"22","author":"Talbi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.ajkd.2024.05.005_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.889923","article-title":"The regulation of adipose tissue health by estrogens","volume":"13","author":"Steiner","year":"2022","journal-title":"Front Endocrinol"},{"issue":"15","key":"10.1053\/j.ajkd.2024.05.005_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"9147","key":"10.1053\/j.ajkd.2024.05.005_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.ajkd.2024.05.005_bib18","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1681\/ASN.2009020162","article-title":"Family history of renal disease severity predicts the mutated gene in ADPKD","volume":"20","author":"Barua","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.05.005_bib19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.05.005_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.05.005_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2024.05.005_bib22","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2024.05.005_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.05.005_bib24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.05.005_bib25","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624008412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624008412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:33:32Z","timestamp":1724355212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624008412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0272638624008412"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.05.005","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visceral Abdominal Adiposity and Autosomal Dominant Polycystic Kidney Disease Progression: One More Step Toward Identifying Useful Biomarkers and Characterizing the Disease Metabolic Links","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.02.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}